Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORM-13070
- Development stage
- Phase 1
- Lead developer
- Orion
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
ORM-13070 is a carbon-11 labeled small molecule radioligand developed by the **University of Turku** in collaboration with **Orion Pharma**. It functions as a positron emission tomography (PET) tracer specifically designed to image and quantify **alpha-2C (α2C) adrenoceptor** binding in the human brain. While α2C-adrenoceptors are potential therapeutic targets for various neuropsychiatric conditions such as depression, schizophrenia, and Alzheimer's disease, ORM-13070 itself is a diagnostic imaging tool rather than a therapeutic agent. It is utilized in clinical research to monitor changes in synaptic noradrenaline concentrations by observing the displacement of the tracer under pharmacological or physiological challenge conditions, such as the administration of ketamine or atomoxetine.
- Other names
- 1-[(S)-1-(2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]-4-(3-11C-methoxymethylpyridin-2-yl)-piperazineORM 13070ORM13070ORM-13070
02
Targets
ADRA2C (α2C)
Beyond the preview
Go deeper on ORM-13070.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ORM-13070.